MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE (MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE).
Monobasic and dibasic sodium phosphate are phosphates that increase urinary phosphate concentration, leading to osmotic diuresis and acidification of urine. They also act as a source of phosphate for metabolic processes.
| Metabolism | Not metabolized; excreted primarily via kidneys. |
| Excretion | Primarily renal excretion as phosphate ions; >95% eliminated via urine; minimal biliary/fecal elimination. |
| Half-life | Not applicable as a true terminal half-life; phosphate clearance is highly dependent on renal function and serum phosphate levels; in patients with normal renal function, serum phosphate returns to baseline within 4-6 hours after oral dose. |
| Protein binding | Not significantly protein bound; inorganic phosphate is freely filtered at the glomerulus; binding to serum proteins is negligible. |
| Volume of Distribution | Approximately 0.25 L/kg; represents total body phosphate distribution, primarily in bone and intracellular compartments. |
| Bioavailability | Oral: ~70-80% absorbed under fasting conditions; absorption can be reduced with food or in hypophosphatemic states. |
| Onset of Action | Oral: Laxative effect typically within 2-6 hours; rectal: within 2-5 minutes. |
| Duration of Action | Oral: Laxative effect lasts 4-6 hours; rectal: duration of enema effect is until bowel evacuation is complete (typically 30 minutes to 1 hour). |
Oral: 1-2 tablets (each containing monobasic sodium phosphate 500 mg and dibasic sodium phosphate 750 mg) 4 times daily, taken with a full glass of water; rectal enema: 120 mL (monobasic sodium phosphate 19 g and dibasic sodium phosphate 7 g) as a single dose, administered rectally.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with GFR <30 mL/min or pre-existing renal impairment; use with caution if GFR 30-50 mL/min, consider dose reduction or alternative therapy; monitor serum electrolytes and renal function. |
| Liver impairment | No specific dose adjustment required for Child-Pugh Class A or B; use with caution in severe hepatic impairment (Child-Pugh Class C) due to potential electrolyte disturbances. |
| Pediatric use | Oral: Children ≥5 years: 1/2 to 1 tablet (monobasic sodium phosphate 250-500 mg and dibasic sodium phosphate 375-750 mg) 4 times daily; enema: Children 2-12 years: 30-60 mL (half strength) as a single dose; infants <2 years: not recommended. |
| Geriatric use | Start with lower doses (e.g., 1 tablet 2-3 times daily) and titrate slowly; monitor renal function and serum electrolytes closely due to increased risk of phosphate accumulation and electrolyte imbalances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE (MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE).
| Breastfeeding | It is not known whether monobasic sodium phosphate and dibasic sodium phosphate are excreted in human breast milk. The M/P ratio has not been determined. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. The potential for adverse effects in the nursing infant (e.g., electrolyte disturbances) should be considered. If used, monitoring of infant serum electrolytes may be warranted. |
| Teratogenic Risk | Based on available data, monobasic sodium phosphate and dibasic sodium phosphate are not associated with an increased risk of major birth defects when used at recommended doses. However, there are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. As a general precaution, use during pregnancy should be limited to situations where clearly needed, especially during the first trimester. Potential risks include electrolyte imbalances (e.g., hyperphosphatemia, hypocalcemia) that may adversely affect fetal development. |
■ FDA Black Box Warning
Risk of acute phosphate nephropathy, particularly in patients with renal impairment, bowel obstruction, or those taking medications affecting renal function. Use with caution; ensure adequate hydration.
| Serious Effects |
Renal impairment (e.g., GFR <30 mL/min), bowel obstruction, gastric retention, megacolon, known hypersensitivity to phosphates, hyperphosphatemia, hypocalcemia, and patients at risk for aspiration.
| Precautions | Risk of acute phosphate nephropathy, hypocalcemia, hypernatremia, dehydration, and cardiac arrhythmias. Monitor renal function, electrolytes, and hydration status. Avoid in patients with renal impairment, bowel obstruction, or impaired gastric motility. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes (including phosphate, calcium, sodium, potassium, magnesium, and chloride), renal function, and acid-base balance prior to and during treatment. In pregnant women, additional monitoring of fetal well-being (e.g., ultrasound for growth and amniotic fluid volume) may be considered, especially in cases of prolonged use or high doses. Assess for signs of fluid overload or electrolyte imbalance in both mother and fetus. |
| Fertility Effects | There are no data on the effects of monobasic sodium phosphate and dibasic sodium phosphate on human fertility. Animal studies have not been conducted to evaluate reproductive toxicity. No known effects on fertility are expected at therapeutic doses, but potential electrolyte disturbances could theoretically impact reproductive function. |